logo SBA

ETD

Archivio digitale delle tesi discusse presso l’Università di Pisa

Tesi etd-06272022-131645


Tipo di tesi
Tesi di laurea magistrale LM6
Autore
AMATO, FEDERICA
URN
etd-06272022-131645
Titolo
Sopravvivenza globale, sopravvivenza libera da malattia e qualità della vita in pazienti affetti da Carcinoma Squamoso dell'Orofaringe p16+ HPV-correlato trattati con Chirurgia robotica trans-orale con/senza terapia adiuvante VS Radioterapia o ChemioRadioterapia
Dipartimento
RICERCA TRASLAZIONALE E DELLE NUOVE TECNOLOGIE IN MEDICINA E CHIRURGIA
Corso di studi
MEDICINA E CHIRURGIA
Relatori
relatore Prof. Casani, Augusto Pietro
correlatore Dott. Fiacchini, Giacomo
Parole chiave
  • Carcinoma Squamoso Orofaringe
  • chemio-radioterapia
  • chirurgia robotica trans-orale
  • HPV
  • qualità della vita
  • radioterapia
  • sopravvivenza globale
  • sopravvivenza libera da malattia
Data inizio appello
12/07/2022
Consultabilità
Non consultabile
Data di rilascio
12/07/2092
Riassunto
Background: Treatment de-intensification for p16+ oropharyngeal squamous cell carcinoma is an area of active research. The rationale for this is to reduce the side effects of these treatments and improve patients’ quality of life. In this paper we evaluated the Overall Survival, the Disease-Free Survival and the quality of life of patients affected by p16+ oropharyngeal squamous cell carcinomas according to their prognostic stage group and their different treatments.
Materials and Methods: Patients were selected retrospectively through our Electronic Tumor Board Database according to specific inclusion criteria. Basic data of eligible patients were recorded and analyzed. Then, the Overall Survival and the Disease-Free Survival were evaluated according to the prognostic stage group and the treatments performed. After that, the eligible patients completed three questionnaires: the Quality of Life Questionnaire Core 30 (QLQ-C30), the Quality of Life Questionnaire Head & Neck 43 (QLQ-HN43) and the MD Anderson Dysphagia Inventory (MDADI) questionnaire.
Results: 61 patients were included in this study. 8 patients died from the disease and the remaining 53 patients completed the 3 questionnaires. 15 (25%) patients were treated with surgery +/- adjuvant therapy, 6 (10%) patients with definitive radiotherapy and 40 (65%) patients with concomitant chemoradiotherapy. Comparing the DFS and the OS of PSG I patients by the different treatments performed, no statistically significant difference was identified. Patients treated with upfront surgery showed statistically significant better outcomes in some aspects of their quality of life.
Conclusion: For p16+ OPSCC PSG I patients, TORS with neck dissection plus/minus adjuvant treatment can be considered a valid alternative to radiotherapy or radiochemotherapy while maintaining a comparable DFS and OS and giving patients better results in terms of specific aspects of their QoL.
File